With an eye to 'non-ob­vi­ous bind­ing sites,' CBC Group launch­es pre­ci­sion med­i­cine play with $67M and ex-Ed­i­tas ex­ec at the helm

Over the past year, CBC Group has been qui­et­ly in­cu­bat­ing a biotech to take ad­van­tage of the AI rush and make some new ther­a­pies against hard-to-drug on­col­o­gy tar­gets. And it’s now en­ticed a tech in­vestor to pick up the tab on the Se­ries A.

EN­SEM Ther­a­peu­tics is launch­ing with $67 mil­lion from GGV Cap­i­tal — which has backed com­pa­nies like Airbnb, Al­iba­ba and Slack — and Pavil­ion Cap­i­tal, Cen­o­va Cap­i­tal, Mit­sui & Co. Glob­al In­vest­ment and CBC Group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER